Is a cure for Parkinson's disease hiding inside us?

Jaime Santos; Irantzu Pallarès; Salvador Ventura

doi:10.1016/j.tibs.2022.02.001

Is a cure for Parkinson's disease hiding inside us?

Trends Biochem Sci. 2022 Aug;47(8):641-644. doi: 10.1016/j.tibs.2022.02.001. Epub 2022 Feb 19.

Authors

Jaime Santos¹, Irantzu Pallarès², Salvador Ventura³

Affiliations

¹ Institut de Biotecnologia i Biomedicina and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.
² Institut de Biotecnologia i Biomedicina and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain. Electronic address: irantzu.pallares@uab.cat.
³ Institut de Biotecnologia i Biomedicina and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain. Electronic address: salvador.ventura@uab.es.

PMID: 35193796
DOI: 10.1016/j.tibs.2022.02.001

Abstract

α-Synuclein (a-syn) oligomers and fibrils are behind neurodegeneration in Parkinson's disease (PD), but therapeutically targeting them is challenging. Amphipathic and cationic helical peptides inhibit amyloid formation and suppress neurotoxicity by selectively binding the solvent-accessible regions in these toxic species. Can endogenous peptides, like LL-37, constitute a new therapeutic paradigm in PD?

Keywords: LL-37; Parkinson’s disease; amyloid fibril; disease-modifying therapy; oligomer; α-synuclein.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Amyloid
Humans
Parkinson Disease* / drug therapy
Parkinson Disease* / metabolism
alpha-Synuclein / metabolism

Substances

Amyloid
alpha-Synuclein